-
What is the drug of choice for hyperuricemia with excessive uric acid production?
Time of Update: 2022-04-27
Glucocorticoids Answer: B Analysis: ① and lupus renal damage The most closely related autoantibodies are anti-dsDNA antibodies, so this topic chooses B.
Link to previous article: What is the closest autoantibody related to lupus kidney damage?
-
These incurable diseases may be a special type of rheumatoid arthritis!
Time of Update: 2022-04-27
The diagnosis of typical rheumatoid arthritis is not difficult, but some special types are often regarded as intractable diseases due to the lack of awareness of patients and even some doctors, which leads to detours in diagnosis and treatment, and even delays the disease.
-
The latest, the first international "myositis" treatment guideline is released, collect it now!
Time of Update: 2022-04-27
① Pediatrics: Early and complete control of muscle weakness and inflammation in adolescent IIM patients should improve outcomes and reduce disease-related complications (1, B, 100%) .
-
How do rheumatoid patients exercise?
Time of Update: 2022-04-27
Exercise not only relieves pain, effectively improves muscle strength and endurance, but also increases joint range of motion to promote venous and lymphatic return, thereby helping to eliminate joint swelling .
-
The gout you suffer from may be "fake"!
Time of Update: 2022-04-27
The deposition of these crystals in the joints can cause an arthritic reaction similar to gout, so this type of disease is called "pseudo-gout" .
Figure 7 Multifocal, clump-like purplish-blue calcified crystal deposits The American Rheumatoid Arthritis Clinical Study Group defined the ultrasound features of CPPD in fibrocartilage, articular cartilage, tendon, and synovial fluid .
-
Ghost Shave only knows Minoxidil?
Time of Update: 2022-04-27
The results of two phase III randomized controlled trials (RCTs) published in the New England Journal of Medicine revealed the efficacy and safety of baricitinib in the treatment of alopecia areata .
-
The team of Wang Honglin, Shanghai Jiaotong University School of Medicine republished innovative results of the treatment of autoimmune diseases with polypeptides encoded in the non-coding regions of the genome in EMBO Reports
Time of Update: 2022-04-27
On March 28, 2022, Wang Honglin's team from the Clinical Research Institute of the First People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine/Precision Research Center for Difficult Diseases published a paper entitled "A peptide encoded by pri-miRNA-31 represses autoimmunity by the classic journal EMBO reports.
-
Immunity Reveals Antitumor Mechanism of Tertiary Lymphoid Structure in Renal Cell Carcinoma Using 10x Genomics Visium FFPE Spatial Transcriptome Technology
Time of Update: 2022-04-26
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer, using 10x Genomics Visium FFPE spatial transcriptome technology to discover Tertiary lymphoid structures (TLS) in renal cell carcinoma are important sites for B cell maturation and differentiation into plasma cells (also called effector B cells), and IgG+ plasma cells are associated with immune checkpoint inhibitor treatment response and progression-free survival in patients showing a positive correlation .
-
This special type of rheumatism, misdiagnosed as a tumor will be fatal!
Time of Update: 2022-04-25
*Only for medical professionals to read and refer to the brain burn cases! Have you encountered a situation in which the superficial phenomenon and the actual cause are difficult to associate with ea
-
Immunity Ruan Haibin's research group discovered a new molecular mechanism of intestinal antiparasitic immunity
Time of Update: 2022-04-25
This study reveals that O-acetylglycosamine modification of STAT6 transcription factor (O-GlcNAc)-mediated expression of Pou2f3 and Gasdermin C (GSDMC) in intestinal epithelial cells is important for cluster cell proliferation and increased interleukin-33 secretion, respectively mechanism .
-
Lancet Rheumatology: Risk of gout and COVID-19 diagnosis and death in UK Biobank: a population-based study
Time of Update: 2022-04-24
This study aimed to assess whether gout is a risk factor for COVID-19 and COVID-19 diagnosis - related death, and to test for sex- and drug-specific risk differences .
-
ACC: Evidence of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine
Time of Update: 2022-04-24
QT prolongation is one of the most common reasons for drug withdrawal from the market by disrupting human ether-a-go-go-related gene ( hERG ) K + channel function .
Correspondingly, chronic and acute treatment of HCQ reduced hERG currents .
Conclusion: We conclude that HCQ reduces mature hERG channel expression and I hERG
-
ARD: A pilot study of baricitinib (JAK inhibitor) in active Sjögren's syndrome
Time of Update: 2022-04-24
ESSDAI , EULAR Patient Reportable Index for Primary SS (ESSPRI) , Physician's Global Assessment (PGA) score and serological measures including erythrocyte sedimentation rate (ESR) , IgG levels, and remission of organ manifestations were assessed .
-
【Professor Lin Jin】Special topic of adult Still's disease: Rheumatologists should always be aware of differential diagnosis
Time of Update: 2022-04-24
Adult onset Still disease (AOSD) is a group of clinical syndromes of unknown etiology, mainly characterized by high fever, transient rash, arthritis, arthralgia, sore throat, and elevated white blood cell count, often accompanied by Liver, spleen, and lymph node enlargement .
-
ARD: Points to be considered for the diagnosis and management of autoinflammatory type I interferon disease (CANDLE/PRAAS, SAVI, and AGS) in the 2021 Consortium of European Societies of Rheumatology/American College of Rheumatology
Time of Update: 2022-04-24
RESULTS: The working group developed consensus and evidence-based guidelines on 4 overarching principles and 17 points for the diagnosis, treatment and long-term monitoring of patients with autoinflammatory interferon disease CANDLE/PRAAS , SAVI and AGS .
-
ARD: Short-, medium-, and long-term risk of acute coronary syndrome in a cohort of RA patients using biological DMARDs: results from four Nordic countries
Time of Update: 2022-04-24
The aim of this study was to compare the 1- , 2- , and 5 -year ACS incidence in patients with RA who were initiated on any of the biological disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice, and with the general population .
-
ARD: Outcome of SARS-CoV-2 infection in children and adolescents with preexisting rheumatic and musculoskeletal disorders
Time of Update: 2022-04-23
Notably, most children and adolescents were not hospitalized with COVID-19 , although those with severe systemic RMD and obesity were more likely to be hospitalized .
Notably, most children and adolescents were not hospitalized with COVID-19 , although those with severe systemic RMD and obesity were more likely to be hospitalized .
-
How to scientifically reduce hormones in SLE patients?
Time of Update: 2022-04-23
Hormones play a vital role in the treatment of SLE, but at the same time, butterfly friends also have certain concerns: if large doses of hormones are given, they are worried about the adverse reactions caused by long-term use, and if the dose of hormones is not increased, they are worried about the recurrence of the disease .
-
Front Pharmacol: Longteng decoction promotes regression of synovial inflammation in mice with collagen-induced arthritis by regulating type 2 innate lymphocytes
Time of Update: 2022-04-23
Conclusion: LTD has been proved to be an effective traditional Chinese medicine formula for the treatment of rheumatoid arthritis , which can reduce joint inflammation and swelling in CIA mice, inhibit the inflammatory infiltration of synovial tissue, and reduce cartilage damage .
-
JAMA Dermatol: Comparison of the efficacy of systemic immunomodulatory therapy for atopic dermatitis
Time of Update: 2022-04-23
Systemic immunomodulators used to treat atopic dermatitis include cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and dupilumab, abrutinib, braziltinib, tralotinib Kinumab and upadacitinib were recently approved in different countries .
7; high certainty) was associated with lower EASI slightly than dupilumab, 600 mg, then 300 mg every 2 weeks .
